tradingkey.logo
tradingkey.logo
Search

Elutia Inc

ELUT
Add to Watchlist
0.880USD
+0.020+2.31%
Market hours ETQuotes delayed by 15 min
38.91MMarket Cap
0.72P/E TTM

More Details of Elutia Inc Company

Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. It is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.

Elutia Inc Profile

Ticker SymbolELUT
Company nameElutia Inc
IPO dateOct 08, 2020
CEOMills (C. Randal)
Number of employees51
Security typeOrdinary Share
Fiscal year-endOct 08
Address12510 Prosperity Drive
CitySILVER SPRING
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code20904
Phone12402471143
Websitehttps://elutia.com/
Ticker SymbolELUT
IPO dateOct 08, 2020
CEOMills (C. Randal)

Company Executives of Elutia Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Matthew B. (Matt) Ferguson
Mr. Matthew B. (Matt) Ferguson
Chief Financial Officer
Chief Financial Officer
480.08K
+1.67%
Mr. Matthew B. (Matt) Ferguson
Mr. Matthew B. (Matt) Ferguson
Chief Financial Officer
Chief Financial Officer
480.08K
+1.67%
Mr. Kevin L. Rakin
Mr. Kevin L. Rakin
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
328.54K
-21.31%
Mr. Kevin L. Rakin
Mr. Kevin L. Rakin
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
328.54K
-21.31%
Mr. Guido J. Neels
Mr. Guido J. Neels
Independent Director
Independent Director
125.00K
--
Mr. Guido J. Neels
Mr. Guido J. Neels
Director
Director
125.00K
--
Dr. Michelle LeRoux Williams, Ph.D.
Dr. Michelle LeRoux Williams, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
118.05K
+6.97%
Dr. Michelle LeRoux Williams, Ph.D.
Dr. Michelle LeRoux Williams, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
118.05K
+6.97%
Mr. David Colpman
Mr. David Colpman
Independent Director
Independent Director
31.10K
--
Mr. David Colpman
Mr. David Colpman
Independent Director
Independent Director
31.10K
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Matthew B. (Matt) Ferguson
Mr. Matthew B. (Matt) Ferguson
Chief Financial Officer
Chief Financial Officer
480.08K
+1.67%
Mr. Matthew B. (Matt) Ferguson
Mr. Matthew B. (Matt) Ferguson
Chief Financial Officer
Chief Financial Officer
480.08K
+1.67%
Mr. Kevin L. Rakin
Mr. Kevin L. Rakin
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
328.54K
-21.31%
Mr. Kevin L. Rakin
Mr. Kevin L. Rakin
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
328.54K
-21.31%
Mr. Guido J. Neels
Mr. Guido J. Neels
Independent Director
Independent Director
125.00K
--
Mr. Guido J. Neels
Mr. Guido J. Neels
Director
Director
125.00K
--

FAQs

Who are the top five shareholders of Elutia Inc?

The top five shareholders of Elutia Inc are: Mr. Matthew B. (Matt) Ferguson

How many institutions hold shares of Elutia Inc (ELUT)?

As of 2026Q1, 59 institutions hold shares of Elutia Inc, with a combined market value of approximately 21.86M, accounting for 49.45% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -5893824.00.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.